Clinical Trial: NCT03913455
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Shadia Jalal, MD |
| Information Provided By: | Hoosier Cancer Research Network |
| Last Update Posted: | 2023-12-20 |
Study Overview
Brief Summary
This is a phase II, open-label, single arm, single-stage study. Both, chemo-sensitive and chemo-resistant patients will be enrolled and treated with 4 cycles of combination of Guadecitabine and carboplatin
Official Title
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Conditions
Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Intervention / Treatment
- Drug: Guadecitabine
- Drug: Carboplatin
Other Study ID Numbers
- HCRN LUN17-302
Start Date (Actual)
2019-06-06
Primary Completion Date (Actual)
2021-04-14
Study Completion Date (Actual)
2022-02-02
Enrollment (Actual)
24
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Shadia Jalal, MD |
| Information Provided By: | Hoosier Cancer Research Network |
| Last Update Posted: | 2023-12-20 |
Study Overview
Brief Summary
This is a phase II, open-label, single arm, single-stage study. Both, chemo-sensitive and chemo-resistant patients will be enrolled and treated with 4 cycles of combination of Guadecitabine and carboplatin
Official Title
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Conditions
Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Intervention / Treatment
- Drug: Guadecitabine
- Drug: Carboplatin
Other Study ID Numbers
- HCRN LUN17-302
Start Date (Actual)
2019-06-06
Primary Completion Date (Actual)
2021-04-14
Study Completion Date (Actual)
2022-02-02
Enrollment (Actual)
24
Study Type
Interventional
Phase
Phase 2